Cargando…
A systematic review of the safety information contained within the Summaries of Product Characteristics of medications licensed in the United Kingdom for Attention Deficit Hyperactivity Disorder. how does the safety prescribing advice compare with national guidance?
BACKGROUND: The safety of paediatric medications is paramount and contraindications provide clear pragmatic advice. Further advice may be accessed through Summaries of Product Characteristics (SPCs) and relevant national guidelines. The SPC can be considered the ultimate independent guideline and is...
Autores principales: | Savill, Nicola, Bushe, Chris J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3317854/ https://www.ncbi.nlm.nih.gov/pubmed/22234242 http://dx.doi.org/10.1186/1753-2000-6-2 |
Ejemplares similares
-
Atomoxetine in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. Systematic Review of Review Papers 2009–2011. An Update for Clinicians
por: Bushe, Chris J., et al.
Publicado: (2011) -
Suicide related events and attention deficit hyperactivity disorder treatments in children and adolescents: a meta-analysis of atomoxetine and methylphenidate comparator clinical trials
por: Bushe, Chris J, et al.
Publicado: (2013) -
The Safety and Efficacy of Methylphenidate and Dexmethylphenidate in Adults with Attention Deficit/Hyperactivity Disorder
por: Sopko, Michael A., et al.
Publicado: (2010) -
Efficacy and Safety of Atomoxetine in the Treatment of Children and Adolescents with Attention Deficit Hyperactivity Disorder
por: Kohn, Michael R., et al.
Publicado: (2012) -
A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities
por: Clemow, David B, et al.
Publicado: (2017)